Clinical Pharmacokinetics, Safety, and Tolerability of a Novel, First-in-Class TRPV4 Ion Channel Inhibitor, GSK2798745, in Healthy and Heart Failure Subjects.
Navin GoyalPete SkrdlaRosemary SchroyerSubramanya KumarDisala FernandoAnna OughtonNicola NortonDennis L SprecherJoseph CheriyanPublished in: American journal of cardiovascular drugs : drugs, devices, and other interventions (2019)
GSK2798745 was well-tolerated in healthy volunteers and patients with stable heart failure. The safety and exposure data obtained in this study allow further evaluation of the drug in long-term clinical studies in heart failure as well as other indications.